AFFX 9.74 Affymetrix $AFFX Hit a 52 week high of 9
Post# of 53482
Posted On: 11/14/2014 10:14:22 AM
AFFX 9.74 Affymetrix $AFFX Hit a 52 week high of 9.83 Closing the day 09:44 at 9.74 +0.05 +0.52% With a day low of 9.70 and a total volume of 63,346.
AFFX Recent Posts: http://investorshangout.com/Affymetrix-AFFX-53256/
AFFX Affymetrix Recent Headline News
'Mad Money' Lightning Round: A Group to Avoid
at The Street - Fri Nov 14, 5:00AM CST
Cramer says he's not going against Affymetrix, and doesn't want to get back into the sand game.
DCT: 8.39 (unch), CBI: 53.49 (-0.02), FMSA: 12.57 (-0.09), KODK: 22.29 (-0.06), WNR: 41.14 (-1.52), FRT: 132.52 (+0.34), ARIA: 6.33 (+0.08), AFFX: 9.71 (+0.02), ADSK: 59.57 (+0.26)
Cramer's Lightning Round - Affymetrix Teased And Disappointed, But Is A Buy (11/13/14)
SA Editor Miriam Metzinger - Seeking Alpha - Fri Nov 14, 2:40AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday November 13. Bullish Calls: Affymetrix (NASDAQ: AFFX ): "This company has over time teased people and then disappointed them, but I believe...
CBI: 53.49 (-0.02), FMSA: 12.57 (-0.09), KODK: 22.29 (-0.06), WNR: 41.14 (-1.52), FRT: 132.52 (+0.34), ARIA: 6.32 (+0.07), ADSK: 59.57 (+0.26), AFFX: 9.71 (+0.02)
Jim Cramer's 'Mad Money' Recap: Market 'Losers' Back in the Game
at The Street - Thu Nov 13, 5:49PM CST
Some stocks written off by this market are looking better than ever, Cramer says.
FLEX: 11.00 (+0.11), KMB: 113.28 (-0.79), M: 62.01 (+0.44), WMT: 82.29 (-0.65), FLTX: 36.53 (-0.45), AFFX: 9.71 (+0.02), DPS: 70.35 (-0.36), DCT: 8.39 (unch), JACK: 71.45 (-0.89), FMSA: 12.57 (-0.09), CSCO: 25.93 (+0.25), CBI: 53.49 (-0.02), KODK: 22.29 (-0.06), DIS: 90.64 (+0.15), WNR: 41.14 (-1.52), FRT: 132.52 (+0.34), BA: 128.57 (+0.04), PLKI: 53.10 (+1.21), AZO: 571.01 (-2.71), JCP: 7.17 (+0.07), JWN: 74.25 (+1.00), ARIA: 6.32 (+0.07), DOW: 50.83 (+0.87), ADSK: 59.57 (+0.26)
Intercept Pharmaceuticals Slumps: ICPT Falls 5.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 7:34AM CST
Intercept Pharmaceuticals has been witnessing a negative trend in its current year earnings estimate and its share price has been falling for past few days
ANIP: 51.78 (+0.31), ICPT: 156.80 (-2.06), AMAG: 34.46 (+0.22), AFFX: 9.71 (+0.02)
Affymetrix Announces Webcast of Investor Day 2014 on Monday November 17, 2014
Business Wire - Wed Nov 12, 6:15AM CST
Affymetrix, Inc. (NASDAQ: AFFX) today announced that the company will host a live webcast in conjunction with its Investor Day on Monday, November 17, 2014 at 11:30 a.m. ET. Presentations from management will include a strategic update from Frank Witney, President & CEO, as well as a financial update from Gavin Wood, EVP & CFO.
AFFX: 9.71 (+0.02)
Affymetrix Launches Solution to Enable Cancer Researchers to Rapidly Map the Functional Impact of DNA Alterations on Gene Expression Profiles to Identify Potential Cancer Driver Events
Business Wire - Wed Nov 12, 5:30AM CST
Affymetrix (NASDAQ:AFFX) announced today the launch of Concurrent Molecular Analysis Profiling (CoMAP(TM)) capability, which enables cancer researchers to gain rapid insight into the functional impact of DNA copy number alterations by combining whole-genome copy number data with gene expression profiles to easily and cost-effectively visualize and identify cancer driver events.
AFFX: 9.71 (+0.02)
Orexigen (OREX) Worth Watching: Stock Soars 33.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 8:25AM CST
Orexigen (OREX) was a big mover last session, with shares surging over 33% on the day.
BIIB: 311.38 (-6.60), OREX: 5.86 (unch), AMAG: 34.46 (+0.22), AFFX: 9.71 (+0.02)
Achillion Pharmaceuticals (ACHN) Looks Strong: Stock Up 27.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 7:44AM CST
Achillion Pharmaceuticals (ACHN) was a big mover last session, as the company saw its shares surge a little over 27% on the day
HSKA: 15.52 (+0.02), ACHN: 14.00 (+0.51), ILMN: 183.23 (-1.77), AFFX: 9.71 (+0.02)
Global Cell and Tissue Culture Supplies Industry
PR Newswire - Mon Nov 10, 5:54PM CST
This report analyzes the worldwide markets for Cell and Tissue Culture Supplies in US$ Thousands by the following Product Segments: Media, Sera, and Reagents. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Latin America. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 67 companies including many key and niche players such as -
AFFX: 9.71 (+0.02)
BIND Therapeutics (BIND) Worth a Look: Stock Rises 5.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 7:30AM CST
BIND Therapeutics, Inc. (BIND) was a big mover last session, as the company saw its shares rise over 5% on the day.
AGEN: 2.99 (+0.01), AMAG: 34.46 (+0.22), BIND: 9.80 (-0.11), AFFX: 9.71 (+0.02)
Update: Affymetrix Posts Encouraging Q3 2014 Earnings
Andy Batts - at Seeking Alpha - Fri Nov 07, 7:41AM CST
AFFX: 9.71 (+0.02)
Looking for a Growth Stock? Why It is Time to Focus on Affymetrix (AFFX) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 7:40AM CST
Affymetrix is one such company that might be well-positioned for future earnings growth as this firm, which is in the healthcare sector, saw EPS growth of 150% last year, and is looking great for this year too
AFFX: 9.71 (+0.02)
Vertex Pharmaceuticals Seeks Approval for CF Combination - Analyst Blog
Arpita Dutt - Zacks Investment Research - Thu Nov 06, 5:25PM CST
Priority review and timely approval would allow Vertex Pharmaceuticals (VRTX) to launch this combination in mid-15 in the U.S.
CYTK: 4.23 (-0.01), BIIB: 311.34 (-6.64), VRTX: 113.21 (+0.49), AFFX: 9.71 (+0.02)
Myriad Genetics Down on Earnings, Revenue Miss in Q1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 2:30PM CST
Myriad Genetics (MYGN) believes the current trajectory of its Hereditary Cancer franchise puts it in a better position to achieve increased profitability and reach its targeted goals.
AGEN: 2.99 (+0.01), MYGN: 32.91 (-0.44), AMAG: 34.46 (+0.22), AFFX: 9.71 (+0.02)
Genomic Health Q3 Loss Narrower than Expected, Revenues Lag - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 1:50PM CST
In the third quarter of 2014, Genomic Health (GHDX) expanded Medicaid coverage for the Oncotype DX breast cancer test, extending coverage to more than 40 million Medicaid patients in 35 states .
AGEN: 2.99 (+0.01), AMAG: 34.46 (+0.22), GHDX: 32.58 (-0.19), AFFX: 9.71 (+0.02)
Celldex (CLDX) in Focus: Stock Tanks 21% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 7:50AM CST
Celldex has been witnessing a flat trend in its current year loss estimates and its share price has been falling for past few days
AGEN: 2.99 (+0.01), CLDX: 13.97 (-0.29), AMAG: 34.46 (+0.22), AFFX: 9.71 (+0.02)
Zacks' Bull Of The Day: Affymetrix
Zacks Investment Research - Seeking Alpha - Wed Nov 05, 1:43PM CST
Headquartered in Santa Clara, California, Affymetrix (NASDAQ: AFFX ) is a leading provider of microarray-based products and services to the global research community. The company utilizes its DNA chip technology in areas of gene expression,...
AFFX: 9.71 (+0.02)
Cytokinetics, Incorporated (CYTK) in Focus: Stock Surges 16.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 8:18AM CST
Cytokinetics, Incorporated (CYTK) was a big mover last session, as the company saw its shares rise by over 16% on the day.
AGEN: 2.99 (+0.01), CYTK: 4.23 (-0.01), AMAG: 34.46 (+0.22), AFFX: 9.71 (+0.02)
Earnings Estimates Moving Higher for Affymetrix (AFFX): Time to Buy? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 7:44AM CST
Affymetrix could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision front and its stock has seen decent short-term momentum
AFFX: 9.71 (+0.02)
Bull of the Day: Affymetrix (AFFX) - Bull of the Day
Neena Mishra - ZACKS - Wed Nov 05, 2:56AM CST
Bull of the Day: Affymetrix (AFFX) - Bull of the Day
AFFX: 9.71 (+0.02)
AFFX Recent Posts: http://investorshangout.com/Affymetrix-AFFX-53256/
AFFX Affymetrix Recent Headline News
'Mad Money' Lightning Round: A Group to Avoid
at The Street - Fri Nov 14, 5:00AM CST
Cramer says he's not going against Affymetrix, and doesn't want to get back into the sand game.
DCT: 8.39 (unch), CBI: 53.49 (-0.02), FMSA: 12.57 (-0.09), KODK: 22.29 (-0.06), WNR: 41.14 (-1.52), FRT: 132.52 (+0.34), ARIA: 6.33 (+0.08), AFFX: 9.71 (+0.02), ADSK: 59.57 (+0.26)
Cramer's Lightning Round - Affymetrix Teased And Disappointed, But Is A Buy (11/13/14)
SA Editor Miriam Metzinger - Seeking Alpha - Fri Nov 14, 2:40AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Thursday November 13. Bullish Calls: Affymetrix (NASDAQ: AFFX ): "This company has over time teased people and then disappointed them, but I believe...
CBI: 53.49 (-0.02), FMSA: 12.57 (-0.09), KODK: 22.29 (-0.06), WNR: 41.14 (-1.52), FRT: 132.52 (+0.34), ARIA: 6.32 (+0.07), ADSK: 59.57 (+0.26), AFFX: 9.71 (+0.02)
Jim Cramer's 'Mad Money' Recap: Market 'Losers' Back in the Game
at The Street - Thu Nov 13, 5:49PM CST
Some stocks written off by this market are looking better than ever, Cramer says.
FLEX: 11.00 (+0.11), KMB: 113.28 (-0.79), M: 62.01 (+0.44), WMT: 82.29 (-0.65), FLTX: 36.53 (-0.45), AFFX: 9.71 (+0.02), DPS: 70.35 (-0.36), DCT: 8.39 (unch), JACK: 71.45 (-0.89), FMSA: 12.57 (-0.09), CSCO: 25.93 (+0.25), CBI: 53.49 (-0.02), KODK: 22.29 (-0.06), DIS: 90.64 (+0.15), WNR: 41.14 (-1.52), FRT: 132.52 (+0.34), BA: 128.57 (+0.04), PLKI: 53.10 (+1.21), AZO: 571.01 (-2.71), JCP: 7.17 (+0.07), JWN: 74.25 (+1.00), ARIA: 6.32 (+0.07), DOW: 50.83 (+0.87), ADSK: 59.57 (+0.26)
Intercept Pharmaceuticals Slumps: ICPT Falls 5.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 13, 7:34AM CST
Intercept Pharmaceuticals has been witnessing a negative trend in its current year earnings estimate and its share price has been falling for past few days
ANIP: 51.78 (+0.31), ICPT: 156.80 (-2.06), AMAG: 34.46 (+0.22), AFFX: 9.71 (+0.02)
Affymetrix Announces Webcast of Investor Day 2014 on Monday November 17, 2014
Business Wire - Wed Nov 12, 6:15AM CST
Affymetrix, Inc. (NASDAQ: AFFX) today announced that the company will host a live webcast in conjunction with its Investor Day on Monday, November 17, 2014 at 11:30 a.m. ET. Presentations from management will include a strategic update from Frank Witney, President & CEO, as well as a financial update from Gavin Wood, EVP & CFO.
AFFX: 9.71 (+0.02)
Affymetrix Launches Solution to Enable Cancer Researchers to Rapidly Map the Functional Impact of DNA Alterations on Gene Expression Profiles to Identify Potential Cancer Driver Events
Business Wire - Wed Nov 12, 5:30AM CST
Affymetrix (NASDAQ:AFFX) announced today the launch of Concurrent Molecular Analysis Profiling (CoMAP(TM)) capability, which enables cancer researchers to gain rapid insight into the functional impact of DNA copy number alterations by combining whole-genome copy number data with gene expression profiles to easily and cost-effectively visualize and identify cancer driver events.
AFFX: 9.71 (+0.02)
Orexigen (OREX) Worth Watching: Stock Soars 33.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 8:25AM CST
Orexigen (OREX) was a big mover last session, with shares surging over 33% on the day.
BIIB: 311.38 (-6.60), OREX: 5.86 (unch), AMAG: 34.46 (+0.22), AFFX: 9.71 (+0.02)
Achillion Pharmaceuticals (ACHN) Looks Strong: Stock Up 27.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 7:44AM CST
Achillion Pharmaceuticals (ACHN) was a big mover last session, as the company saw its shares surge a little over 27% on the day
HSKA: 15.52 (+0.02), ACHN: 14.00 (+0.51), ILMN: 183.23 (-1.77), AFFX: 9.71 (+0.02)
Global Cell and Tissue Culture Supplies Industry
PR Newswire - Mon Nov 10, 5:54PM CST
This report analyzes the worldwide markets for Cell and Tissue Culture Supplies in US$ Thousands by the following Product Segments: Media, Sera, and Reagents. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Latin America. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 67 companies including many key and niche players such as -
AFFX: 9.71 (+0.02)
BIND Therapeutics (BIND) Worth a Look: Stock Rises 5.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 7:30AM CST
BIND Therapeutics, Inc. (BIND) was a big mover last session, as the company saw its shares rise over 5% on the day.
AGEN: 2.99 (+0.01), AMAG: 34.46 (+0.22), BIND: 9.80 (-0.11), AFFX: 9.71 (+0.02)
Update: Affymetrix Posts Encouraging Q3 2014 Earnings
Andy Batts - at Seeking Alpha - Fri Nov 07, 7:41AM CST
AFFX: 9.71 (+0.02)
Looking for a Growth Stock? Why It is Time to Focus on Affymetrix (AFFX) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 7:40AM CST
Affymetrix is one such company that might be well-positioned for future earnings growth as this firm, which is in the healthcare sector, saw EPS growth of 150% last year, and is looking great for this year too
AFFX: 9.71 (+0.02)
Vertex Pharmaceuticals Seeks Approval for CF Combination - Analyst Blog
Arpita Dutt - Zacks Investment Research - Thu Nov 06, 5:25PM CST
Priority review and timely approval would allow Vertex Pharmaceuticals (VRTX) to launch this combination in mid-15 in the U.S.
CYTK: 4.23 (-0.01), BIIB: 311.34 (-6.64), VRTX: 113.21 (+0.49), AFFX: 9.71 (+0.02)
Myriad Genetics Down on Earnings, Revenue Miss in Q1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 2:30PM CST
Myriad Genetics (MYGN) believes the current trajectory of its Hereditary Cancer franchise puts it in a better position to achieve increased profitability and reach its targeted goals.
AGEN: 2.99 (+0.01), MYGN: 32.91 (-0.44), AMAG: 34.46 (+0.22), AFFX: 9.71 (+0.02)
Genomic Health Q3 Loss Narrower than Expected, Revenues Lag - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 1:50PM CST
In the third quarter of 2014, Genomic Health (GHDX) expanded Medicaid coverage for the Oncotype DX breast cancer test, extending coverage to more than 40 million Medicaid patients in 35 states .
AGEN: 2.99 (+0.01), AMAG: 34.46 (+0.22), GHDX: 32.58 (-0.19), AFFX: 9.71 (+0.02)
Celldex (CLDX) in Focus: Stock Tanks 21% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 7:50AM CST
Celldex has been witnessing a flat trend in its current year loss estimates and its share price has been falling for past few days
AGEN: 2.99 (+0.01), CLDX: 13.97 (-0.29), AMAG: 34.46 (+0.22), AFFX: 9.71 (+0.02)
Zacks' Bull Of The Day: Affymetrix
Zacks Investment Research - Seeking Alpha - Wed Nov 05, 1:43PM CST
Headquartered in Santa Clara, California, Affymetrix (NASDAQ: AFFX ) is a leading provider of microarray-based products and services to the global research community. The company utilizes its DNA chip technology in areas of gene expression,...
AFFX: 9.71 (+0.02)
Cytokinetics, Incorporated (CYTK) in Focus: Stock Surges 16.2% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 8:18AM CST
Cytokinetics, Incorporated (CYTK) was a big mover last session, as the company saw its shares rise by over 16% on the day.
AGEN: 2.99 (+0.01), CYTK: 4.23 (-0.01), AMAG: 34.46 (+0.22), AFFX: 9.71 (+0.02)
Earnings Estimates Moving Higher for Affymetrix (AFFX): Time to Buy? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 7:44AM CST
Affymetrix could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision front and its stock has seen decent short-term momentum
AFFX: 9.71 (+0.02)
Bull of the Day: Affymetrix (AFFX) - Bull of the Day
Neena Mishra - ZACKS - Wed Nov 05, 2:56AM CST
Bull of the Day: Affymetrix (AFFX) - Bull of the Day
AFFX: 9.71 (+0.02)
(0)
(0)Scroll down for more posts ▼